Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 30, 2016 - Issue 5
Submit an article Journal homepage
1,179
Views
1
CrossRef citations to date
0
Altmetric
Articles; Medical Biotechnology

The anti-tumour effect of a DNA vaccine carrying a fusion gene of human VEGFR2 and IL-12

Sha WenDepartment of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. ChinaView further author information
,
Jia ZhangDepartment of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. ChinaView further author information
,
Ping ZhouDepartment of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. ChinaView further author information
,
Cheng LuoDepartment of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. ChinaView further author information
,
Yingfu LiuDepartment of Cell Biology, Logistics University of China People's Armed Police Forces, Tianjin, P.R. ChinaView further author information
,
Zhongwei XuCentral Laboratory, Logistics University of China People's Armed Police Forces, Tianjin, P.R. ChinaView further author information
,
Xiaoyi ChenDepartment of Cell Biology, Logistics University of China People's Armed Police Forces, Tianjin, P.R. ChinaView further author information
&
Houxun MaDepartment of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Pages 956-962 | Received 22 Jan 2016, Accepted 27 Jun 2016, Published online: 05 Aug 2016

References

  • Yang B, Jeang J, Yang A, et al. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153–3164.
  • Pol J, Bloy N, Obrist F, et al. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology [ Internet]. 2014 [ cited 2016 Jan 3];3(1):e28185. Available from: http://dx.doi.org/10.4161/onci.23803.
  • Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther. 2014;14(3):170–189.
  • Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209.
  • Walther W, Schlag PM. Current status of gene therapy for cancer. Curr Opin Oncol. 2013;25(6):659–664.
  • Chiarella P, Fazio VM, Signori E. Electroporation in DNA vaccination protocols against cancer. Curr Drug Metab. 2013;14(3):291–299.
  • Khan KH. DNA vaccines: roles against diseases. Germs. 2013;3(1):26–35.
  • Russo G, Mischi M, Scheepens W, et al. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110(11 Pt C):E794–E808.
  • Nakagami H, Morishita R. Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis. Expert Opin Biol Ther. 2015;15(3):431–436.
  • Hu Q, Wu M, Fang C, et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 2015;15(4):2732–2739.
  • Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Seminars Cancer Biol. 2015;35(suppl):S224–S243.
  • Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471–494.
  • Lucas ML, Heller L, Coppola D, et al. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5(6):668–675.
  • Dabrowska A, Giermasz A, Golab J, et al. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma. 2001;48(5):358–361.
  • Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64(5):842–848.
  • Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520–3526.
  • Wang Y, Zhang J, Wu Y, et al. Mannan-modified adenovirus targeting TERT and VEGFR-2: a universal tumour vaccine. Sci Rep [Internet]. 2015 [ cited 2016 Jun 23];5:11275. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471666/.
  • Tagliamonte M, Petrizzo A, Tornesello ML, et al. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother. 2014;10(11):3332–3346.
  • Gardlik R, Behuliak M, Palffy R, et al. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 2011;18:425–431.
  • Niethammer AG, Lubenau H, Mikus G, et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer [ Internet]. 2012 [ cited 2015 Dec 20];12:361. Available from: http://dx.doi.org/10.1186/1471-2407-12-361.
  • Xu WW, Li B, Lam AK, et al. Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget. 2015;6(3):1790–1805.
  • Zhao X, Bose A, Komita H, et al. Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012;188(4):1782–1788.
  • Maranda E, Robak T. Biological properties and clinical significance of interlenkins12(IL-2). Postepy Hig Med Dosw. 1998;52:489–506.
  • Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term anti-tumor memory by interleukin-l2 electro-gene therapy. J Natl Cancer Inst. 2002;94(10):762–768.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.